Abstract
This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to summarize the effect of resveratrol intake on weight loss. We searched the following databases until July 2018: MEDLINE, EMBASE, Web of Science and Cochrane Central Register of Controlled Trials. Data were pooled using the inverse variance method and expressed as standardized mean difference (SMD) with 95% confidence intervals (95% CI). Out of 831 reports, 36 RCTs were eligible for including to our meta-analysis. The pooled results, using random-effects model showed that resveratrol supplementation significantly decreased body weight (SMD = −0.17; 95% CI, −0.33, −0.01; P = 0.03; I2: 62.6), body mass index (BMI) (SMD = −0.20; 95% CI, −0.35, −0.05; P = 0.01; I2: 60.6), fat mass (SMD = −0.32; 95% CI, −0.62, −0.03; P = 0.03; I2: 77.9) and waist circumference (WC) (SMD = −0.42; 95% CI, −0.68, −0.16; P = 0.001; I2: 75.2), and significantly increased lean mass (SMD = 1.21; 95% CI, 0.75, 1.67; P < 0.001; I2: 87.6). We found no significant effect of resveratrol administration on leptin (SMD = −0.20; 95% CI, −0.68, 0.27; P = 0.40; I2: 85.3) and adiponectin levels (SMD = 0.08; 95% CI, −0.39, 0.55; P = 0.74; I2: 91.0). Resveratrol supplementation significantly decreased body weight in obese patients (SMD −0.43; 95% CI, −0.60, −0.26) compared with other diseases (SMD 0.02; 95% CI, −0.29, 0.33), and type 2 diabetes mellitus (SMD −0.17; 95% CI, −0.37, 0.02). Overall, the current meta-analysis demonstrated that resveratrol intake significantly reduced weight, BMI, WC and fat mass, and significantly increased lean mass, but did not affect leptin and adiponectin levels.
Acknowledgments
The present study was supported by a grant from the Vice-chancellor for Research, SUMS, Shiraz, and Iran.
Disclosure statement
The authors declare no conflict of interest.